Publications - Group members - Tumor Immunology & Immunotherapy Group

Selected publications

FPR2 Shapes an Immune-Excluded Pancreatic Tumor Microenvironment and Drives T-cell Exhaustion in a Sex-Dependent Manner.
He F, Tay AHM, Calandigary A, Malki E, Suzuki S, Liu T, Wang Q, Fernández-Moro C, Kaisso M, Olofsson-Sahl P, Melssen M, Sze SK, Björnstedt M, Löhr MJ, Karlsson MCI, Heuchel R, Sarhan D
Cancer Res 2023 May;83(10):1628-1645

Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer.
Sarhan D, Eisinger S, He F, Bergsland M, Pelicano C, Driescher C, Westberg K, Benitez II, Humoud R, Palano G, Li S, Carannante V, Muhr J, Önfelt B, Schlisio S, Ravetch JV, Heuchel R, Löhr MJ, Karlsson MCI
iScience 2022 Nov;25(11):105317

Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L, Botling J, He F, Pelicano C, Zhou C, He C, Palano G, Mezheyeuski A, Micke P, Ravetch JV, Karlsson MCI, Sarhan D
Cancer Res 2021 Feb;81(4):956-967

Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function.
Sarhan D, Wang J, Sunil Arvindam U, Hallstrom C, Verneris MR, Grzywacz B, Warlick E, Blazar BR, Miller JS
JCI Insight 2020 Mar;5(5):

Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
Eisinger S, Sarhan D, Boura VF, Ibarlucea-Benitez I, Tyystjärvi S, Oliynyk G, Arsenian-Henriksson M, Lane D, Wikström SL, Kiessling R, Virgilio T, Gonzalez SF, Kaczynska D, Kanatani S, Daskalaki E, Wheelock CE, Sedimbi S, Chambers BJ, Ravetch JV, Karlsson MCI
Proc Natl Acad Sci U S A 2020 Dec;117(50):32005-32016

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS
Blood Adv 2018 Jun;2(12):1459-1469

Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.
Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS
Cancer Immunol Res 2018 Jul;6(7):766-775

Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.
Lövgren T, Sarhan D, Truxová I, Choudhary B, Maas R, Melief J, Nyström M, Edbäck U, Vermeij R, Scurti G, Nishimura M, Masucci G, Karlsson-Parra A, Lundqvist A, Adamson L, Kiessling R
Cancer Immunol Immunother 2017 Oct;66(10):1333-1344

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno S, Tuininga K, Dougherty P, McCullar V, Howard P, Sarhan D, Taras E, Schlums H, Abbot S, Shoemaker D, Bryceson YT, Blazar BR, Wolchko S, Cooley S, Miller JS
Cancer Res 2017 Oct;77(20):5664-5675

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.
Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, Verneris MR, Blazar BR, Miller JS
Cancer Res 2016 Oct;76(19):5696-5706